What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy and safety of sonrotoclax-based triplet therapy in treatment-naïve mantle cell lymphoma.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Prospective study demonstrates effective triplet regimen in untreated mantle cell lymphoma, suggesting targeted therapy improves patient outcomes.

To evaluate the efficacy and safety of sonrotoclax-based triplet therapy in treatment-naïve mantle cell lymphoma.
Open-label, single-arm, multicenter trial with treatment-naïve MCL patients.
Patients received zanubrutinib and zuberitamab as lead-in treatment followed by sonrotoclax.
Treatment included 12 cycles of triplet therapy with monitoring for complete remission and safety.
86.7% of enrolled patients had advanced stage mantle cell lymphoma.
At Cycle 6, 80% of evaluable patients achieved complete remission.
Manageable treatment-related adverse events were reported, with no major safety concerns observed.

Qiu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Prospective study demonstrates effective triplet regimen in untreated mantle cell lymphoma, suggesting targeted therapy improves patient outcomes.